TENX (Tenax Therapeutics) Total Liabilities: $8.49 Mil (As of Mar. 2026)


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $15.49
! 3 Warning Signs
View Full Analysis

What is Tenax Therapeutics Total Liabilities?

Tenax Therapeutics TENX +16.42% 22 Total Liabilities is $8.49 Mil as of Mar. 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Tenax Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $8.49 Mil.

Tenax Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($6.60 Mil) to Dec. 2025 ($7.16 Mil) and increased from Dec. 2025 ($7.16 Mil) to Mar. 2026 ($8.49 Mil).

Tenax Therapeutics's annual Total Liabilities increased from Dec. 2023 ($3.59 Mil) to Dec. 2024 ($4.69 Mil) and increased from Dec. 2024 ($4.69 Mil) to Dec. 2025 ($7.16 Mil).

Tenax Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Tenax Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics Total Liabilities Chart

Tenax Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.91 3.59 4.69 7.16

Tenax Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 2.53 6.60 7.16 8.49
TENX
22GF Score
Tenax Therapeutics Inc TENX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tenax Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.156+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.16

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=104.227-97.071
=7.16

Tenax Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.486+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.49

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=123.178-114.692
=8.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $8.49 Mil mean?
Tenax Therapeutics (TENX) has a Total Liabilities of $8.49 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Tenax Therapeutics and its competitors.
Is Tenax Therapeutics' Total Liabilities too high?
Tenax Therapeutics' current Total Liabilities is $8.49 Mil. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Total Liabilities compare to RCKT and AVIR?
Tenax Therapeutics' Total Liabilities of $8.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Tenax Therapeutics and its competitors. Tenax Therapeutics's current Total Liabilities is $8.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Total Liabilities of $8.49 Mil. The current Total Liabilities is $8.49 Mil. Tenax Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Total Liabilities is $8.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.49
Price